Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PER2 | O15055 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27904403 | 0.76 | SMN1; SMN2 (0.33) | MITFSMN1; SMN2PER2LMNA | |
| SCHEMBL12494650 | 0.74 | KMT2A (0.40) | MITFSMN1; SMN2KMT2ABRD4BRD2 | |
| SCHEMBL477281 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL2728747 | 0.70 | SMN1; SMN2 (0.44) | MITFSMN1; SMN2KMT2ALMNAALDH1A1 | |
| SCHEMBL2815518 | 0.70 | ALDH1A1 (0.36) | SMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL22635867 | 0.69 | BRD4 (0.41) | MITFSMN1; SMN2PER2BRD4BRD2 | |
| SCHEMBL27731773 | 0.68 | MITF (0.34) | MITFSMN1; SMN2PER2ALDH1A1 | |
| SCHEMBL3695373 | 0.68 | — | — | |
| SCHEMBL7029657 | 0.67 | BRD4 (0.39) | MITFSMN1; SMN2KMT2ABRD4BRD2 | |
| SCHEMBL27648790 | 0.67 | MITF (0.36) | MITFSMN1; SMN2PER2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935815-B2 | Imidazoyl pyridine compounds and salts thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009619-A1 | POLYCYCLIC COMPOUND | APP, BACE1, PSEN1 | MITF 2925/4885SMN1; SMN2 1063/4885PER2 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.